CytoDyn Inc., investor presentation, June 21, 2021 (Exhibit 99.2 to Form 8-K, June 21, 2021)

Summary

CytoDyn Inc.'s investor presentation of June 21, 2021, filed as Exhibit 99.2 to a Form 8-K, on Vyrologix (leronlimab, PRO 140), a humanized monoclonal antibody. It presents results from the CD-15 trial in COVID-19 long-haulers, symptom by symptom, using a repeated measures model that it states was not pre-specified, with p-values for each symptom. It lists programmes in COVID-19 long-haulers and critically ill and severe patients, including in Brazil, India and the Philippines, and in HIV, cancer, NASH and stroke. For HIV it describes a Phase 3 monotherapy label expansion, a once-monthly PrEP programme and a cure trial on the Timothy Brown model. It gives a Samsung BioLogics contract minimum of 1 million vials a year and current inventory of 1.1 million vials.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

JUNE 21, 2021 INVESTOR PRESENTATION
Vyrologix (leronlimab – PRO 140) The pursuit of precision medicine Humanized Monoclonal Antibody CytoDyn Inc. Exhibit 99.2

Forward-Looking Statements &
Information This presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current
prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean
that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to provide positive health outcomes, the possible results of clinical trials, studies or other programs or ability to
continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company's forward-looking statements are not guarantees of performance, and actual results could vary materially
from those contained in or expressed by such statements due to risks and uncertainties including: (i) the regulatory determination of leronlimab’s efficacy to treat COVID-19 by the U.S. Food and Drug Administration and various drug regulatory
agencies in other countries, (ii) the Company's ability to raise additional capital to fund its operations, (iii) the Company's ability to meet its debt obligations, if any, (iv) the Company's ability to enter into partnership or licensing
arrangements with third parties, (v) the Company's ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company's ability to achieve approval of a marketable product, (vii) the design, implementation and
conduct of the Company's clinical trials, (viii) the results of the Company's clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the
existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company's products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory
approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company's control. The Company urges investors to consider
specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by
law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this presentation.

Robust Pipeline – Leronlimab
COVID-19 Long-Hauler CD15 Exploratory Symptoms/Biomarkers CD18 Phase 3: Biomarker/Symptoms/Autonomic/PFT CD19 Phase 2: Biomarker after treatment CD20 Phase 2: Biomarker/Cognitive CD21 Phase 2: Biomarker/MRI fibrosis COVID-19 trials Critically ill
Severe BLA submission Cancer program mTNBC Basket trial Requesting Pre-BLA meeting with the FDA NASH trial CT1 and PDFF + Biomarker Stroke RTT data promising Biomarker

Models for the raw ordinal data would
not converge. This might be due to the study sample size and small cell sizes for each severity and treatment group combination. A model for daily change from baseline as a continuous variable was fit. Accounting for all daily data in a repeated
measures model is thought to be a more precise method than only using a single day, however it was not pre-specified. Specifically, terms for treatment and a baseline covariate were included as fixed-effects with a repeated effect for time. Every
symptom converged for this model. CD-15: Long-Hauler Symptoms Repeated Measures Statistical Analysis

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Joint Pain & Swelling Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 0 2 1 3 Moderate 2 4 14 9 7 Mild 1 12 9 4 7 None 0 12 3 14 11 20 43 25 30 -23 -5 LL better 360% Repeated
Measures p-value < 0.0001

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Tightness in Chest Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 0 6 2 3 Moderate 2 4 5 5 4 Mild 1 8 7 3 9 None 0 16 10 18 12 16 35 19 26 -19 -7 LL better 171% Repeated Measures
p-value < 0.0001

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Tingling or Numbness Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 1 5 1 1 Moderate 2 1 5 3 6 Mild 1 9 12 7 10 None 0 17 6 17 11 14 37 16 25 -23 -9 LL better 156% Repeated
Measures p-value < 0.0001

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Muscle Weakness Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 1 5 2 4 Moderate 2 4 15 6 8 Mild 1 14 5 8 12 None 0 9 3 12 4 25 50 26 40 -25 -14 LL better 79% Repeated Measures
p-value = 0.013

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Sleep Disturbance (Insomnia) Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 2 10 4 8 Moderate 2 1 12 4 11 Mild 1 13 4 11 7 None 0 12 2 9 2 21 58 31 53 -37 -22 LL better 68%
Repeated Measures p-value = 0.01

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Headache Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 1 5 3 4 Moderate 2 1 10 3 9 Mild 1 12 10 6 8 None 0 15 3 16 7 17 45 21 38 -28 -17 LL better 65% Repeated Measures p-value
< 0.0001

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Shortness of Breath Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 0 5 2 3 Moderate 2 4 10 5 8 Mild 1 11 6 6 11 None 0 13 7 15 6 19 41 22 36 -22 -14 LL better 57% Repeated
Measures p-value = 0.032

CD-15: Long-Hauler Symptoms Primary
Endpoint baseline thru day 56 Average Nausea Leronlimab Leronlimab Placebo Placebo Day 56 Baseline Day 56 Baseline Severe 3 0 1 0 2 Moderate 2 0 7 1 6 Mild 1 4 5 7 6 None 0 24 15 20 14 4 22 9 24 -18 -15 LL better 20% Repeated Measures p-value =
0.028

Robust Pipeline – Leronlimab
COVID-19 Long-Hauler COVID-19 Critically ill COVID-19 Severe Brazil India Philippines Other

Robust Pipeline – Leronlimab
Biomarker and Mechanism of Action Laboratory work finding MOA of leronlimab for each indication Dosage of leronlimab

Program Status HIV- Monotherapy
Phase 3, label expansion, protocol submitted to the US FDA HIV - PrEP One dose/month – Phase 2 – Animal study was very successful for use of leronlimab in PrEP for one dose per month. Publication has been submitted to journal and
potential Phase 2 is to initiate in 2021. HIV - Cure 5 patients/Timothy Brown model – Phase 2 – This trial is currently searching for potential HIV patient who is in need of bone marrow transplant similar to Timothy Brown. If leronlimab
can mimic the delta-32 during a bone marrow transplant by covering all the CCR5 receptor, then the result could be a cure. First patient injection could be 2021. Role of Leronlimab in HIV (Summary) Monotherapy, PrEP and Cure

BLA HIV Draft Dose Justification
Report 30-JUN-21 Includes Virology Data Analysis Receptor Occupancy Plan CD02 and CD03 VF data with ADA and Population PK analysis Completion to allow for rolling submission: BLA Module 1 Administrative 15-Jul-21 BLA Module 2 – CTD Summaries
CMC 30-Jul-21 BLA Module 2 – CTD Summaries non-CMC 01-Sep-21 BLA Module 3 – Quality/CMC 30-Jul-21 BLA Module 4- Non-Clinical Reports 15-Jul-21 BLA Module 5- Clinical Reports 15-Oct-21 Leronlimab Opportunity Multiple Indications

Leronlimab Opportunity Multiple
Indications Triple-Negative Breast cancer results in 4-6 months NASH complete enrollment of initial 60 patients end of June NASH enrollment for biomarkers and CT1/PDFF completion Q4 2021 Long-Hauler Phase 3 completion Q4 2021

Leronlimab Opportunity Multiple
Indications 2021 BLA submission completion Critical COVID-19 completion Severe-to-critical COVID-19 completion Long-Hauler phase 3 results HIV PrEP initiate NASH trial results MOA results with dosage finding (loading/normal dose) Breakthrough
Therapy designation for mTNBC filed

Deal signed April 2019 Completion of
first batch of clinical grade leronlimab in June 2020 Completion of batches of commercial grade leronlimab in calendar 3Q20-4Q20 Leronlimab Manufacturing Samsung BioLogics (Commercial Partnership) Initial forecast made calendar 1Q20 Updated forecast
provided quarterly Order for 2022 and 2023 at new facility at Samsung Contract minimum - 1 million vials/yr Current inventory – 1.1 million vials 2022- 1 million vials minimum 2023 - 2 million vials minimum Order for 2022 and 2023 at new
facility at Samsung

File and source

File

SEC_CYDY_8-K_filed2021-06-21_0001193125-21-195277_EX-99.2.htm

Size

17,235 bytes

SHA-256

9d6bea47e46afab5481b11f7369452b3145964a249de138fc199c021acbe174f

Our copy

SEC_CYDY_8-K_filed2021-06-21_0001193125-21-195277_EX-99.2.htm

Original

www.sec.gov